CDK5 Protein

CDK5 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CDK5 Protein</th>
</tr>
<tr>
<td class="label">Phosphorylation Site</td>
<td>AD Relevance</td>
</tr>
<tr>
<td class="label">Ser202</td>
<td>Early marker</td>
</tr>
<tr>
<td class="label">Thr205</td>
<td>AD-specific</td>
</tr>
<tr>
<td class="label">Ser396</td>
<td>Late-stage</td>
</tr>
<tr>
<td class="label">Ser404</td>
<td>Disease-progression</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Site</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>Ser202, Thr205, Ser396, Ser404</td>
</tr>
<tr>
<td class="label">α-Synuclein</td>
<td>Ser129</td>
</tr>
<tr>
<td class="label">PSD-95</td>
<td>Ser295</td>
</tr>
<tr>
<td class="label">GluA1</td>
<td>Ser831</td>
</tr>
<tr>
<td class="label">GluN2B</td>
<td>Ser1116</td>
</tr>
<tr>
<td class="label">Synapsin I</td>
<td>Ser10</td>
</tr>
<tr>
<td class="label">MEF2</td>
<td>Multiple sites</td>
</tr>
<tr>
<td class="label">p53</td>
<td>Ser15</td>
</tr>
<tr>
<td class="label">Inhibitor</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Roscovitine</td>
<td>CDK2/5/7/9</td>
</tr>
<tr>
<td class="label">Purvalanol A</td>
<td>CDK2/5</td>
</tr>
<tr>
<td class="label">AT7519</td>
<td>Multi-CDK</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a h

CDK5 Protein

Overview

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">CDK5 Protein</th>
</tr>
<tr>
<td class="label">Phosphorylation Site</td>
<td>AD Relevance</td>
</tr>
<tr>
<td class="label">Ser202</td>
<td>Early marker</td>
</tr>
<tr>
<td class="label">Thr205</td>
<td>AD-specific</td>
</tr>
<tr>
<td class="label">Ser396</td>
<td>Late-stage</td>
</tr>
<tr>
<td class="label">Ser404</td>
<td>Disease-progression</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Site</td>
</tr>
<tr>
<td class="label">Tau</td>
<td>Ser202, Thr205, Ser396, Ser404</td>
</tr>
<tr>
<td class="label">α-Synuclein</td>
<td>Ser129</td>
</tr>
<tr>
<td class="label">PSD-95</td>
<td>Ser295</td>
</tr>
<tr>
<td class="label">GluA1</td>
<td>Ser831</td>
</tr>
<tr>
<td class="label">GluN2B</td>
<td>Ser1116</td>
</tr>
<tr>
<td class="label">Synapsin I</td>
<td>Ser10</td>
</tr>
<tr>
<td class="label">MEF2</td>
<td>Multiple sites</td>
</tr>
<tr>
<td class="label">p53</td>
<td>Ser15</td>
</tr>
<tr>
<td class="label">Inhibitor</td>
<td>Selectivity</td>
</tr>
<tr>
<td class="label">Roscovitine</td>
<td>CDK2/5/7/9</td>
</tr>
<tr>
<td class="label">Purvalanol A</td>
<td>CDK2/5</td>
</tr>
<tr>
<td class="label">AT7519</td>
<td>Multi-CDK</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">300 edges</a></td>
</tr>
</table>

Protein Architecture

The active site is located in the cleft between the two lobes and contains essential catalytic residues including Asp127 (catalytic aspartate), Lys33 (ATP phosphate anchor), and the HRD motif (His124-Arg125-Asp126) that functions as the catalytic loop. Unlike most CDKs, CDK5 does not require phosphorylation of the T-loop (activation segment) for activity; rather, activity is conferred primarily by binding to the regulatory subunit p35 or p39.

The critical regulatory mechanism involves calpain-mediated cleavage of p35 to generate p25 (residues 99-396). This cleavage removes the membrane-targeting domain and generates a more stable CDK5 activator that relocalizes to the cytosol and nucleus. The p25-CDK5 complex has a longer half-life than the p35-CDK5 complex, leading to prolonged and dysregulated kinase activity[@cruz2003].

Cyclin-Dependent Kinase 5 (CDK5) is a unique member of the cyclin-dependent kinase family with neuron-specific functions critical for brain development, synaptic plasticity, and neuronal survival. Unlike other CDKs that regulate cell cycle progression, CDK5 is activated by neuron-specific regulatory subunits p35 and p39 and participates in virtually every aspect of neuronal biology. The dysregulation of CDK5 activity has been strongly implicated in the pathogenesis of multiple neurodegenerative diseases, particularly Alzheimer's disease where hyperactive CDK5 phosphorylates tau at pathological sites and contributes to synaptic dysfunction and neuronal death[@tsai1993].

CDK5 is encoded by the CDK5 gene located on chromosome 7q36 and produces a 33 kDa protein composed of 292 amino acids. The kinase is expressed predominantly in post-mitotic neurons throughout the central and peripheral nervous systems, with highest expression in the cerebral cortex, hippocampus, basal ganglia, and cerebellum. CDK5 activity is tightly regulated under normal physiological conditions, with dysregulation occurring in response to various pathological stimuli including amyloid-beta (Aβ) exposure, oxidative stress, and excitotoxicity. The generation of the truncated p25 fragment from the physiological p35 activator represents a key molecular switch that converts CDK5 from a protective to a pathological enzyme[@patrick1999].

Structure and Catalytic Mechanism

Protein Architecture

CDK5 possesses the characteristic bilobal kinase fold common to all protein kinases, consisting of an N-terminal lobe (residues 1-90) and a C-terminal lobe (residues 91-292). The N-terminal lobe is primarily composed of β-strands and contains the glycine-rich loop (residues 33-38) that participates in ATP binding. The C-terminal lobe is predominantly α-helical and contains the activation segment (residues 156-171) that regulates kinase activity through phosphorylation[@ahlijanian2000].

The active site is located in the cleft between the two lobes and contains essential catalytic residues including Asp127 (catalytic aspartate), Lys33 (ATP phosphate anchor), and the HRD motif (His124-Arg125-Asp126) that functions as the catalytic loop. Unlike most CDKs, CDK5 does not require phosphorylation of the T-loop (activation segment) for activity; rather, activity is conferred primarily by binding to the regulatory subunit p35 or p39.

Activation Mechanism

CDK5 activation requires binding to one of two neuron-specific activator proteins:

p35 (CDK5R1): A 396-amino acid protein expressed primarily in the brain. p35 contains a myristoylation signal at its N-terminus that anchors it to the membrane, localizing CDK5 activity to membrane-associated compartments. The binding of p35 to CDK5 induces a conformational change that positions the activation segment in an active configuration and aligns catalytic residues for substrate phosphorylation[@dhavan2001].

p39 (CDK5R3): A 369-amino acid protein with 57% homology to p35. p39 is expressed in overlapping but distinct brain regions compared to p35, suggesting region-specific regulation of CDK5 activity. Like p35, p39 can be cleaved to generate p29, though this cleavage occurs less frequently.

The critical regulatory mechanism involves calpain-mediated cleavage of p35 to generate p25 (residues 99-396). This cleavage removes the membrane-targeting domain and generates a more stable CDK5 activator that relocalizes to the cytosol and nucleus. The p25-CDK5 complex has a longer half-life than the p35-CDK5 complex, leading to prolonged and dysregulated kinase activity[@cruz2003].

Normal Physiological Functions

Neuronal Development

CDK5 plays essential roles in brain development through phosphorylation of substrates that regulate:

Neuronal migration: CDK5 phosphorylates filamin A and related proteins to modulate cytoskeletal dynamics required for neuronal migration during corticogenesis. CDK5 knockout mice exhibit severe neuronal migration defects and die perinatally.

Axon guidance and growth cone dynamics: CDK5 regulates growth cone collapse in response to guidance cues by phosphorylating proteins involved in actin cytoskeleton remodeling including cofilin and SCG10.

Synaptogenesis: During development, CDK5 activity regulates the formation and maturation of excitatory synapses. CDK5 phosphorylates PSD-95 and other scaffolding proteins to influence synaptic density and composition.

Synaptic Plasticity

CDK5 is a critical regulator of synaptic plasticity underlying learning and memory:

Long-term potentiation (LTP): CDK5 phosphorylates multiple proteins involved in LTP including NMDA receptor subunits, AMPA receptor subunits, and CaMKII substrates. Paradoxically, both excessive and insufficient CDK5 activity impair LTP, indicating that precise regulation is essential.

Long-term depression (LTD): CDK5 regulates AMPA receptor internalization during LTD through phosphorylation of the GluA1 subunit and associated proteins. CDK5 activity is required for proper LTD expression.

Presynaptic function: At presynaptic terminals, CDK5 phosphorylates synapsin I and other proteins involved in neurotransmitter release, regulating vesicle cycling and release probability[@qu2007].

Gene Expression Regulation

CDK5 translocates to the nucleus where it phosphorylates transcription factors:

• MEF2: Regulates activity-dependent gene expression required for neuronal survival
• p53: Modulates expression of pro-apoptotic genes
• CREB: Regulates transcription of plasticity-related genes
• NF-κB: Influences inflammatory gene expression in neurons

Role in Alzheimer's Disease

CDK5 has emerged as one of the most important kinases in Alzheimer's disease pathogenesis, contributing to multiple disease hallmarks:

Tau Hyperphosphorylation

CDK5 phosphorylates tau at multiple sites that are hyperphosphorylated in AD brains:

The p25-CDK5 complex exhibits enhanced tau kinase activity compared to p35-CDK5, and increased p25 generation in AD brains correlates with the extent of tau pathology. CDK5-mediated phosphorylation of tau reduces its ability to bind microtubules and promotes its aggregation into paired helical filaments[@shah2019].

Synaptic Dysfunction

CDK5 dysregulation directly contributes to synaptic impairment in AD:

AMPA receptor trafficking: CDK5 phosphorylates GluA1 at Ser831 to modulate AMPA receptor insertion during LTP. Aberrant CDK5 activity disrupts this process, contributing to synaptic failure.

NMDA receptor regulation: CDK5 phosphorylates the GluN2B subunit to modulate NMDA receptor function. Altered CDK5 activity affects NMDA receptor trafficking and downstream signaling.

Postsynaptic density organization: CDK5 phosphorylates PSD-95 and other scaffolding proteins, disrupting the organization of postsynaptic specializations and weakening synaptic structures[@sung2021].

Aβ-Induced CDK5 Dysregulation

Amyloid-beta oligomers trigger CDK5 hyperactivation through multiple mechanisms:

Calcium-mediated calpain activation: Aβ exposure increases intracellular calcium, activating calpain which cleaves p35 to p25. This generates the more stable p25-CDK5 complex with prolonged activity.

p35 expression changes: Aβ alters p35 gene expression, increasing the p25/p35 ratio. This shift favors hyperactive CDK5 complexes.

Mislocalization: p25-CDK5 relocalizes to different cellular compartments including the nucleus, where it phosphorylates substrates not normally accessible to p35-CDK5[@lee2020].

Role in Parkinson's Disease

CDK5 involvement in Parkinson's disease has become increasingly evident:

α-Synuclein Phosphorylation

CDK5 phosphorylates α-synuclein at Ser129, the major pathological phosphorylation site found in Lewy bodies:

• Approximately 90% of α-synuclein in Lewy bodies is phosphorylated at Ser129
• CDK5, along with casein kinases, is responsible for this phosphorylation
• Phosphorylation at Ser129 promotes α-synuclein aggregation and toxicity
• Inhibition of CDK5 reduces Ser129 phosphorylation and attenuates α-synuclein pathology in models

Dopaminergic Neuron Vulnerability

CDK5 contributes to the selective vulnerability of dopaminergic neurons in the substantia nigra:

• p35 expression is relatively high in dopaminergic neurons
• These neurons exhibit baseline CDK5 activity that may predispose them to dysregulation
• Environmental toxins (MPTP, rotenone) that cause PD-like pathology activate CDK5
• CDK5 inhibition protects dopaminergic neurons from various insults

Interaction with LRRK2

Recent evidence suggests crosstalk between CDK5 and LRRK2 (Leucine-Rich Repeat Kinase 2), a major PD risk gene:

• LRRK2 mutations cause familial PD with α-synuclein pathology
• CDK5 can phosphorylate LRRK2, potentially regulating its kinase activity
• Both kinases converge on common substrates involved in synaptic function and neuronal survival[@malli2019]

Role in Other Neurodegenerative Diseases

Huntington's Disease

In Huntington's disease, mutant huntingtin protein activates CDK5 through multiple mechanisms:

• Alters calpain activity, increasing p25 generation
• Dysregulates p35 expression
• CDK5 hyperactivation contributes to striatal neuron death
• CDK5 inhibition provides neuroprotection in cellular and animal models

Amyotrophic Lateral Sclerosis

CDK5 dysregulation in ALS involves:

• TDP-43 pathology: CDK5 phosphorylates TDP-43, influencing its aggregation and subcellular localization
• Excitotoxicity: CDK5 modulates AMPA receptor function, potentially contributing to excitotoxic motor neuron death
• Axonal transport defects: CDK5 phosphorylates proteins involved in axonal transport

Frontotemporal Dementia

CDK5 contributes to the tau pathology in frontotemporal dementias through similar mechanisms as in AD. The p25-CDK5 complex is elevated in FTD brains with tau pathology.

Interaction Network

CDK5 interacts with numerous proteins that regulate its activity and substrate specificity:

Activators and Regulators

• p35 (CDK5R1): Primary neuronal activator, membrane-associated
• p39 (CD5R3): Alternative neuronal activator with distinct expression
• p25: Truncated p35, generates hyperactive CDK5 complexes
• p29: Truncated p39, similar to p25

Substrates (Selected)

Therapeutic Approaches

ATP-Competitive Inhibitors

Traditional CDK inhibitors target the ATP-binding site:

These inhibitors face challenges including lack of CDK5 selectivity, poor brain penetration, and toxicity from inhibiting other CDKs essential for cell function.

p25-Targeted Approaches

Novel strategies target the pathogenic p25-CDK5 interaction:

• Peptide inhibitors: Cell-penetrating peptides that disrupt p25-CDK5 binding
• Allosteric inhibitors: Compounds that bind outside the ATP site to allosterically inhibit p25-CDK5
• p35 stabilizers: Compounds that prevent p35 cleavage to p25

Neuroprotective Strategies

• Calpain inhibitors: Prevent p35 cleavage to p25
• Antioxidants: Reduce oxidative stress that activates calpain
• Anti-inflammatory agents: Address neuroinflammation that contributes to CDK5 dysregulation

Animal Models

Knockout Mice

CDK5 knockout mice are embryonic lethal, exhibiting severe neuronal migration defects. Conditional knockouts using Cre-lox technology have revealed specific functions in different neuronal populations.

p25 Transgenic Models

Transgenic mice expressing p25 under inducible promoters have been instrumental:

• p25 expression causes tau hyperphosphorylation and aggregation
• Leads to synaptic loss and cognitive deficits
• Reversible models demonstrate that p25 withdrawal can reverse some pathology
• Useful for testing therapeutic interventions

Biomarker Potential

Fluid Biomarkers

• CSF p25 levels may indicate CDK5 dysregulation
• Phospho-tau species generated by CDK5 could serve as biomarkers
• Changes in CSF p25 correlating with disease progression

Clinical Utility

• Biomarkers could guide patient selection for CDK5 inhibitor trials
• Monitor treatment response to CDK5-targeted therapies

See Also

• [CDK5 Gene](/genes/cdk5)
• [GSK3B Protein](/proteins/gsk3b-protein)
• [Tau Protein](/proteins/tau)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synuclein](/proteins/alpha-synuclein)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)

External Links

• [UniProt: Q00535](https://www.uniprot.org/uniprot/Q00535)
• [PDB: 1H4L](https://www.ebi.ac.uk/pdbe/alpha/1H4L)
• [GeneCards: CDK5](https://www.genecards.org/cgi-bin/carddisp.pl?gene=CDK5)

References